RNAscope ISH to empower Immuno-Oncology Research
RNAscope™ Applications
Immuno-oncology Research
The field of immuno-oncology (IO) and cancer immunotherapy has expanded rapidly in recent years with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches such as cancer vaccines and chimeric antigen receptor T-cell (CAR-T) therapy.
However, our understanding of the function of immune cells, as well as the interactions of different cell types, in the tumor microenvironment (TME) is still limited. New targets and modulators for cancer therapy in the TME continue to be discovered, yet the tools to investigate these in tumor tissue are often lacking. While immunohistochemistry (IHC) is the conventional method of choice, its use is often limited because of the lack of specific and sensitive antibodies.
The RNAscope technology enables rapid and efficient detection of co-expression profiles of any target mRNAs, including checkpoint and cell-specific markers, with single-molecule sensitivity and high specificity in formalin-fixed paraffin-embedded (FFPE) tissues.
Download the Full Presentation
Presented at: 34th Annual SITC Meeting in Maryland
Title: Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology
Authors: Courtney Anderson1, Helly Pimentel1, Helen Jarnagin1, Hailing Zong1, Courtney Todorov1, Kenneth Ganley2, Fay Eng2, Kevin Friedman2, Molly Perkins2, Shannon Grande2, Bingqing Zhang1, Christopher Bunker1, James Rottman2, Xiao-Jun Ma1
1 ACD/Bio-Techne, Newark, CA, 2 Bluebird Bio, Cambridge, MA
White Paper
Foundations of Immuno-oncology: Advancing Basic Science & Translational Research
In this eBook, we examine the complexity of the tumor microenvironment, explore technologies that are innovating basic and translational research, and strategies that are advancing immunotherapy into the clinic.
Topics covered:
- Tumor Microenvironment
- Immune Checkpoints
- Therapeutic Monoclonal Antibodies
- Small Molecules & Immuno-Oncology
- Cell-based Therapeutics
- Cytokines and Immunotherapy
- Tools to Advance Your Immuno-Oncology Research
ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment
ACD conducted a study to analyze the co-expression of 8 checkpoint markers in 60 Non-Small Cell Lung Carcinoma FFPE tissues. Figure 1 illustrates an example of co-detection of these markers in a sample. This study reveals a heterogeneous pattern of expression in different tumor tissues as well as intratumor heterogeneity within each tumor and potential insight into combination therapies targeted against different checkpoint pathways. Study data and results are discuss in the webinar accessible below.
Figure 1: The manual RNAscope 2.5 HD Duplex assay was used to detect expression of the immune checkpoint markers PD-L1 (green chromogen) and PD-1, PD-L2, CTLA4, LAG3, TIM3 or 4-1BB (red chromogen) in human NSCLC tumor samples. PD-L1 and PD-L2 are primarily expressed in the tumor region and co-expressed in the same tumor cells. CTLA4, 4-1BB, PD1, LAG3, and TIM3 are expressed primarily in the stromal regions. Arrows indicate cells co-expressing PD-L1 with LAG3, TIM3, or PD-L2.
Recorded Webinar
Watch this recorded webinar (June 30th, 2016) to learn more about the ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment, presented by Jeffrey Kim, Research Scientist at ACD.
Watch Webinar
Poster
Conventional type 1 dendritic cells and natural killer cells demonstrate strong correlation to cytotoxic T lymphocyte infiltration in cervical cancer tumors
Download Poster
Immune profiling the tumor microenvironment with RNA and protein biomarkers by fluorescence multiplex RNA in situ hybridization and immunohistochemistry.
Download Poster
Evaluation of the Expression of Immune Functional Markers in the Tumor Microenvrionment (TME)
Download Poster
Application note
ACD evaluated the performance of the RNAscope assay in the detection of a wide range of important immuno-oncology markers, including 12 immune checkpoint markers (i.e., PD-L1, CTLA-4, IDO1), 14 immune cell markers (i.e., CD3, CD4, CD8) and 24 immune function markers (i.e., IFNG,TGFB, IL6, CXCL10) in multiple FFPE human tumor samples.
Application Note
Application note "Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay'
Appendix
Appendix "Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay"
Download Immuno-Oncology probe list
(click on gene name to access corresponding RNAscope probes)
Don’t find our gene of interest in this list? Search in our Catalog Target Probe or submit your sequence for a Made to Order Target Probe
